In this slide show we highlight some of the top news on gynecologic cancers in 2017, including studies on surgery for cervical and ovarian cancer, the FDA approval of niraparib, and more.
Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer
The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.
Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Uterine Cancer Survival Rates Have Improved Despite Higher Mortality Risks
Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.
Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy
Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.
Abemaciclib Plus Hormonal Therapy Shows Promising Efficacy in LGSOC/EEC
The adverse effect profile of abemaciclib plus hormonal therapy was comparable with prior reports of CDK4/6 inhibitors.
Puxitatug Samrotecan Exhibits Efficacy in Advanced/Metastatic EC
Puxitatug samrotecan was well tolerated in patients with advanced or metastatic endometrial cancer.